May and Baker Launches Malact to Combat Malaria

Must Read

How To Block Your Bank Account And SIM Card In Case Of Emergency

Losing your phone and wallet or having them stolen can be very frustrating. However, in case that happens to...

List of First Bank of Nigeria Sort Codes in Nigeria

The sort code is a number that usually identifies both the bank and the branch where an account is held. The sort...

List of Access Bank Sort Codes & Branches (with addresses) in Nigeria

The sort code is a number which usually identifies both the bank and the branch where an account is...
- Advertisement -

May & Baker Nigeria Plc, a local pharmaceutical company, has introduced a new anti-malarial drug to treat malaria in the country. The new drug, Malact, is a dihydroartemisinin-piperaquine combination-based formulation that claims to achieve fast relief from malaria and guarantee improved post-treatment protection.

With increasing resistance to older drugs, the World Health Organisation (WHO) years back jettisoned Chloroquine and recommended Artemisinin-based Combination Therapies (ACTs) as the first-line drug for the treatment of uncomplicated malaria.

May and Baker Launches Malact to Combat Malaria Brandspurng
Pharm Obinna Emeribe, Head of Marketing, Pharm Chukutem Chukuka, Executive Director, Pharma Sales & Marketing, Pharm Nnamdi Okafor, Managing Director/CEO and Pharm Yetunde Adigun, Head, Pharma Plant Operations, all of May & Baker Nigeria PLC at the Media Launch of Malact tablets, the company’s new anti.-malarial medicine in Lagos recently. | www.brandspurng.com

However, most ACTs have since shown limitations including resistance to treatment. But the dihydroartemisinin-piperaquine combination, the newer artemisinin-based combination therapy has shown improved efficacy in multiple trials and is considered the most promising drug currently available for the treatment of uncomplicated malaria.

The combination is said to have reliable efficacy guaranteeing patients faster relief compared to other ACTs available in the market. It is also believed to have better post-treatment protection because of its piperaquine content that makes it possible for patients not to experience relapse for at least six weeks.

- Advertisement -

Malact, May & Baker’s new product, is said to prevent malaria for up to six weeks and prevent recrudescence of malaria. Other advantages of Malact include convenient dosing because it is taken once a day and this reduces the chances of dosage non-compliance. It does not require to be taken with fatty meals by the patient before it can be absorbed.

At a media launch of the new anti-malaria product in Lagos, Mr. Nnamdi Okafor, Managing Director/CEO, May & Baker Nigeria Plc. said the introduction of Malact is part of the company’s effort at continually confronting the malaria scourge by providing effective and affordable medicines for the treatment of the disease.

Read Also:  NTA Acquires Right To Broadcast The English Premier League In Nigeria

He said that Malact is the latest and most effective arsenal in the toolbox for the fight against malaria. He said the goal of May & Baker is to continue to be the one-stop-shop for quality antimalarials.

Mr. Chukutem Chukuka, executive director, Pharma Sales & Marketing of May & Baker in his remark said

“Malact has a reliable efficacy which guarantees patient faster relief compared to other ACTs currently available in the market. It also has better posttreatment protection because of the piperaquine content that makes it possible for patients not to experience relapse for at least six weeks. Malact, therefore, prevents malaria for up to six weeks and prevents the recrudescence of malaria”.

- Advertisement -
Read Also:  BLOODLESS MALARIA TEST BY 24 YEAR-OLD UGANDAN WINS THE AFRICA PRIZE FOR ENGINEERING INNOVATION

According to the World Health Organization, Malaria remains a major global health challenge with over 200 million cases annually in Africa. It is responsible for over100, 000 deaths in Nigeria every year.

In addition to the loss of life, malaria places an economic burden on African nations that is estimated to be worth over $12 billion in direct cost and GDP loss annually.

The introduction of the believed more efficacious dihydro artemin ism piperaquine-based antimalarial drug is, therefore, a great relief that promises to reduce malaria-related mortality. May & Baker is Nigeria’s first pharmaceutical company with over 76 years’ experience of doing business in the country.

- Advertisement -
May and Baker Launches Malact to Combat Malaria - Brand SpurMay and Baker Launches Malact to Combat Malaria - Brand Spur

Subscribe to BrandSpur Ng

Subscribe for latest updates. Signup to best of brands and business news, informed analysis and opinions among others that can propel you, your business or brand to greater heights.

- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.

May and Baker Launches Malact to Combat Malaria - Brand SpurMay and Baker Launches Malact to Combat Malaria - Brand Spur

Latest News

Borderless Work: Avon HMO Partners With HR Expo Africa

Recognizing staff wellbeing as a bedrock of organizational performance, Avon HMO was a proud partner at the just concluded...
- Advertisement -
BrandsPur Weekly Cartoons
- Advertisement -May and Baker Launches Malact to Combat Malaria - Brand SpurMay and Baker Launches Malact to Combat Malaria - Brand Spur